Molecular rationale for combining targeted agents to treat breast cancer

A new study provides a rational for treating breast cancer by combining two kinds of targeted agents, one that inhibits an overactive, cancer-causing signaling pathway in cancer cells and one that reverses changes that silence genes that normally prevent cancer. Both types of agents are currently available and being evaluated individually in clinical trials.

Read the whole article on Science Daily

More from Science Daily